To explore the pathogenesis and course prediction of novel coronavirus pneumonia (COVID-19) severe patients

Serum and urine proteins and metabolomic markers in patients with COVID-19

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000031365

Enrollment

Unknown

Registered

2020-03-29

Start date

2020-01-17

Completion date

Unknown

Last updated

2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT

Index test:Proteomics,&#32

and&#32

Eligibility

Sex/Gender

All

Age

1 Years to 80 Years

Inclusion criteria

Inclusion criteria: We anticipate collecting 200 COVID-19 serum samples (40 severe patients, 130 non-severe patients and 30 influza patients) in 2-4 hospitals. At present, there are two cooperate unit, Taizhou Hospital of Zhejiang Province and the First Hospital of Jiangxing. Severe patients include three categories: good prognosis, poor prognosis under cytokine storm and poor prognosis without cytokine storm. We will collect serum, urine and feces samples at multiple time points during the course of the disease to conduct multi-omics analysis.

Exclusion criteria

Exclusion criteria: Death was excluded. Cases with BMI mismatch were excluded

Design outcomes

Primary

Measure	Time frame
proteomics;metabonomics;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactHaixiao Chen

Taizhou Hospital of Zhejiang Province

chenhx@enzemed.com+86 13706760666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026